ACCREDITATION STATEMENT
THE ENDOCRINE SOCIETY HAS NOT DESINGATED THIS ACTIVITY FOR CME CREDIT.
STATEMENT OF INDEPENDENCE
The Endocrine Society has a policy of ensuring that the content and the quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of The Endocrine Society's Clinical Endocrinology Update (CEU) Steering Committee. The commercial supporters of the live activity had no influence over the selection of the faculty or specific presentations.DISCLAIMER
The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of The Endocrine Society.LEARNING OBJECTIVES
Upon completion of this educational activity, learners will be able to:
- Discuss state-of-the-art research in endocrinology
- Demonstrate updated knowledge of the diagnosis and treatment of diabetes, lipid, osteoporosis, pituitary, adrenal, thyroid, and reproductive endocrine disorders
- Employ enhanced skills and practice management techniques to improve patient care
TARGET AUDIENCE
This independent medical education activity should be of substantial interest to endocrinologists, endocrine fellows, internists, healthcare professionals who treat endocrine disorders, and others seeking an update in recent developments in the treatment of endocrine disorders.DISCLOSURE POLICY
The faculty, committee members, and staff involved in planning this independent medical education activity are required to disclose to learners any relevant financial relationship(s) that have occurred within the last 12 months with any commercial interest(s) whose products or services are discussed in the CME content. Such relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent faculty with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments. It remains for learners to determine whether financial interests or relationships may influence the educational activity with regard to exposition or conclusion.The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
The following faculty reported relevant financial relationships:
- Sarah L. Berga, MD: Advisory board member, Agile Therapeutics, Noven Pharmaceutical, Promedica Communications-Bayer Pharmaceutical, Teva Pharmaceutical Industries, Ltd, Watson Pharmaceutical; Consultant, AHC Media, LLC, Pfizer
- Shalender Bhasin, MD: Investigator, Abbott, Ligand Pharmaceuticals
- David R. Clemmons, MD: Advisory board member, Lilly; Consultant, Ipsen, Pfizer
- Bryan R. Haugen, MD: Investigator, Veracyte; Speaker, Genzyme
- Natasa Janicic, MD, PhD: Speaker, Otsuka
- Jack Leahy, MD: Advisory board member, Bristol Myers Squibb, Merck & Co, Inc., Novo Nordisk Inc., sanofi-aventis, Inc., Takeda Pharmaceuticals North America; Investigator and salary recipient, Takeda Pharmaceuticals North America, Inc.
- Aaron Michels, MD: Consultant, sanofi-aventis; Patents: Compounds that modulate autoimmunity and methods of using same- 2848-109-PCT & Compositions, methods and uses for treating diabetes
- Alvin C. Powers, MD: Investigator, Eli Lilly
- Matthew Ringel, MD: Advisory board member, Veracyte; Co-investigator, Esai, Exelixis; Consultant, AstraZeneca
- S. Bobo Tanner, MD: Speaker, Amgen, Lilly, Merck, Novartis
- Andrea L. Utz, MD: Advisory board member, Ipsen
- Nelson Watts, MD: Co-founder, Director, Shareholder, OsteoDynamics; Consultant, Amgen, Baxter, Bristol-Myers Squibb, Imagepace, Lilly, Medpace, Merck, Orexigen, Pfizer/Wyeth; Research grant support, Amgen, Merck, NPS Pharmaceuticals; Speaker, Amgen, Novartis, Warner Chilcott
The following faculty reported NO relevant financial relationships: Erik Alexander, MD; John D. Brunzell, MD; Marcelle I. Cedars, MD; Dima L. Diab, MD; Peter Kopp, MD; Robert A. Levine, MD, FACE; Stephen J. Marx, MD; Arturo R. Rolla, MD; Marcella D. Walker, MD; William F. Young, Jr., MD, MSc.
The following CEU Steering Committee members who planned and/or reviewed content for this activity reported relevant financial relationships:
- Steven T. Harris, MD, FACP: Consultant, Amgen, Eli Lilly & Co., Gilead Sciences, Merck, Roche; Speaker, Amgen, Eli Lilly & Co., Genentech, Gilead Sciences, Novartis, Roche, sanofi-aventis, Warner Chilcott
- Steven P. Hodak, MD: Speaker, Novartis
- Kathryn Martin, MD: Employee, UpToDate
- Mark E. Molitch, MD: Investigator, Corcept, Eli Lilly & Co., Endo, Novartis, Novo-Nordisk, Reata, sanofi-aventis; Monitoring board member, Abbott Laboratories; Shareholder, Abbott Laboratories, Amgen
- Steven Nagelberg, MD: Speaker, Lilly, Merck, Novo Nordisk
- Guillermo Umpierrez, MD: Research grant support, American Diabetes Association, NIH, sanofi-aventis, Baxter, Takeda, Lilly
The following CEU Steering Committee members who planned and/or reviewed content for this activity reported NO relevant financial relationships: Susan Kirk, MD
The Endocrine Society staff associated with the development of the content for this activity reported no relevant financial relationships.
CONFLICT OF INTEREST STATEMENT
The scientific content of this activity was developed by The Endocrine Society's CEU Steering Committee, independent of grant support and in accordance with the ACCME's Essential Areas and Elements, including the Standards for Commercial Support. The commercial supporters of this meeting have no influence over topics or speakers.POLICY ON UNLABELED/OFF-LABEL USE
The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation.Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such "off-label" use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.
PRIVACY & CONFIDENTIALITY STATEMENT
The Endocrine Society will record learner's personal information as provided on evaluations. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its educational offerings program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.ACKNOWLEDGEMENT OF COMMERCIAL SUPPORT
The live activity from which this material is produced was supported by educational grants from Amgen, Endo Pharmaceuticals Inc., Genentech, Inc., Pfizer, Inc., & sanofi-aventis U.S.METHOD OF PARTICIPATION
This enduring material is presented in an online/computer-based format. System requirements include:
- For Windows, Firefox 1.5 or Internet Explorer 7.0 with Flash 8 or better installed.
- For Macintosh OS X, Safari 2.0 or Firefox 1.5 with Flash 8 or better installed.
Last Review Date: September 2011
For technical assistance or information, please contact call 972-910-6899 (Monday - Friday 9:00 AM to 5:00 PM EST) or E-mail: multiviewMediaSupport@multiview.com.
For questions about content, please contact The Endocrine Society at education@endo-society.org.